Ann: Acrux Receives FDA Approval - Generic Testosterone Solution, page-36

I bought in the Part F of the $30,000 worth of shares / 191,000 shares @0.157 the day after the SPP was released, so I am under the assumption i jagged in early to get the allocations at these levels.

Generic pipeline is a smart strategy as it spits in cashflow moving forward while they work on their own products to FDA approval.
No need for reliance on R&D incentives and leftover cash reserves or CR to keep the company moving forward if the generics is providing the basis of cashflow to cover costings.

I really enjoy the new strategy and seems there is more education in the direction of ACR.